tiprankstipranks
Advertisement
Advertisement

DE:2QK Stock Latest News

Scholar Rock receives fast track designation from FDA for apitegromab
The FlyScholar Rock receives fast track designation from FDA for apitegromab
5d ago
SRRK
Scholar Rock price target raised to $64 from $58 at Wedbush
PremiumThe Fly
Scholar Rock price target raised to $64 from $58 at Wedbush
17d ago
SRRK
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance
PremiumThe Fly
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance
17d ago
NVO
SRRK
Scholar Rock price target raised to $63 from $56 at JPMorgan
PremiumThe Fly
Scholar Rock price target raised to $63 from $56 at JPMorgan
21d ago
SRRK
Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status
PremiumThe Fly
Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status
21d ago
SRRK
Scholar Rock Readies for Apitegromab Launch Amid Risks
PremiumCompany AnnouncementsScholar Rock Readies for Apitegromab Launch Amid Risks
25d ago
SRRK
Scholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFA
Premium
Ratings
Scholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFA
28d ago
SRRK
Scholar Rock to remove Catalent Indiana facility from apitegromab BLA
Premium
The Fly
Scholar Rock to remove Catalent Indiana facility from apitegromab BLA
1M ago
NVO
SRRK
Scholar Rock price target raised to $76 from $70 at BMO Capital
PremiumThe Fly
Scholar Rock price target raised to $76 from $70 at BMO Capital
1M ago
SRRK
Scholar Rock price target raised to $60 from $58 at Citi
PremiumThe Fly
Scholar Rock price target raised to $60 from $58 at Citi
1M ago
SRRK
Scholar Rock: Buy Rating Reiterated as Apitegromab Advances Toward PDUFA; $65 Price Target Maintained
PremiumRatings
Scholar Rock: Buy Rating Reiterated as Apitegromab Advances Toward PDUFA; $65 Price Target Maintained
1M ago
SRRK
Scholar Rock Expands $200 Million At-The-Market Program
PremiumCompany Announcements
Scholar Rock Expands $200 Million At-The-Market Program
1M ago
8K
SRRK
Scholar Rock reports Q2 EPS (84c), consensus (84c)
PremiumThe FlyScholar Rock reports Q2 EPS (84c), consensus (84c)
1M ago
SRRK
Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA
Premium
The Fly
Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA
2M ago
NVO
SRRK
Scholar Rock Shareholders Reaffirm Board, Governance and Oversight
Premium
Company Announcements
Scholar Rock Shareholders Reaffirm Board, Governance and Oversight
3M ago
8K
SRRK
Scholar Rock Charts High-Stakes Path to SMA Launch
PremiumCompany Announcements
Scholar Rock Charts High-Stakes Path to SMA Launch
4M ago
SRRK
Scholar Rock Charts Path to Apitegromab Approval
PremiumCompany Announcements
Scholar Rock Charts Path to Apitegromab Approval
4M ago
SRRK
JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’
PremiumThe Fly
JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’
4M ago
SRRK
Scholar Rock price target raised to $55 from $53 at Barclays
PremiumThe Fly
Scholar Rock price target raised to $55 from $53 at Barclays
4M ago
SRRK
Scholar Rock price target raised to $65 from $58 at H.C. Wainwright
PremiumThe FlyScholar Rock price target raised to $65 from $58 at H.C. Wainwright
4M ago
SRRK
Scholar Rock reports Q1 EPS (83c), consensus (78c)
Premium
The Fly
Scholar Rock reports Q1 EPS (83c), consensus (78c)
4M ago
SRRK
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches
Premium
Company Announcements
Scholar Rock Advances Apitegromab Toward Potential 2026 Launches
4M ago
8K
SRRK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >